Delphine Loirat Selected Research

Delphine Loirat Research Topics

Disease

18	Triple Negative Breast Neoplasms 04/2024 - 01/2021
17	Breast Neoplasms (Breast Cancer) 05/2024 - 02/2017
17	Neoplasms (Cancer) 02/2024 - 10/2016
5	Brain Neoplasms (Brain Tumor) 05/2024 - 01/2021
4	Disease Progression 04/2024 - 01/2021
3	Circulating Neoplastic Cells 11/2023 - 06/2017
3	Neoplasm Metastasis (Metastasis) 01/2023 - 09/2022
2	Febrile Neutropenia 04/2024 - 01/2021
2	Inflammatory Breast Neoplasms 01/2023 - 12/2021
2	Neutropenia 10/2022 - 01/2021
2	Diarrhea 10/2022 - 01/2021
1	Septic Shock (Toxic Shock Syndrome) 10/2023
1	Colitis 10/2023
1	Fatigue 10/2023
1	Squamous Cell Carcinoma of Head and Neck 11/2021
1	Microsatellite Instability 11/2021
1	Necrosis 01/2021
1	Leukopenia 01/2021
1	Cytopenia 01/2021
1	Anemia 01/2021
1	Adenocarcinoma 05/2020

Drug/Important Bio-Agent (IBA)

8	sacituzumab govitecanIBA 04/2024 - 01/2021
6	Hormones (Hormone)IBA 05/2024 - 01/2021
5	Gemcitabine FDA Link 10/2022 - 01/2021
4	Capecitabine (Xeloda)FDA Link 04/2024 - 01/2021
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 01/2023
4	Carboplatin (JM8)FDA LinkGeneric 01/2024 - 01/2022
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2017
3	pembrolizumabIBA 03/2024 - 01/2022
3	Immunoconjugates (Immunoconjugate)IBA 02/2024 - 01/2021
3	Surface Antigens (Surface Antigen)IBA 02/2024 - 01/2021
3	durvalumabIBA 01/2024 - 11/2023
3	ErbB Receptors (EGF Receptor)IBA 11/2023 - 10/2022
3	olaparibIBA 12/2022 - 01/2021
3	eribulin FDA Link 10/2022 - 01/2021
3	Vinorelbine (Navelbine)FDA LinkGeneric 10/2022 - 01/2021
3	AntigensIBA 10/2022 - 10/2016
2	trastuzumab deruxtecanIBA 05/2024 - 04/2024
2	Trastuzumab (Herceptin)FDA Link 04/2024 - 09/2021
2	human ERBB2 proteinIBA 02/2024 - 01/2024
2	Fulvestrant (Faslodex)FDA Link 02/2024 - 01/2021
2	Irinotecan (Camptosar)FDA LinkGeneric 10/2022 - 01/2021
2	palbociclibIBA 01/2021 - 01/2020
2	Estrogen ReceptorsIBA 01/2021 - 01/2020
1	EnzymesIBA 04/2024
1	tucatinibIBA 04/2024
1	Everolimus FDA Link 02/2024
1	Cell-Free Nucleic AcidsIBA 02/2024
1	veliparibIBA 01/2024
1	taxaneIBA 10/2023
1	atezolizumabIBA 01/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2022
1	Poly Adenosine Diphosphate RiboseIBA 12/2022
1	Immunoglobulin IsotypesIBA 10/2022
1	Cyclin-Dependent Kinase 4IBA 10/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Farnesyltranstransferase (Farnesyltransferase)IBA 11/2021
1	Tyrosine Kinase InhibitorsIBA 11/2021
1	tipifarnib (R115777)IBA 11/2021
1	pertuzumabIBA 09/2021
1	LTX-315IBA 01/2021
1	Circulating Tumor DNAIBA 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021
1	dimemorfan (AT 17)IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	HaptoglobinsIBA 01/2021
1	Bevacizumab (Avastin)FDA Link 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	Ado-Trastuzumab EmtansineIBA 12/2020
1	AntibodiesIBA 05/2020
1	Tn antigenIBA 05/2020
1	GlycopeptidesIBA 05/2020
1	VaccinesIBA 05/2020
1	CarbohydratesIBA 05/2020
1	Complement System Proteins (Complement)IBA 05/2020
1	thymidine kinase 1IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	CytokinesIBA 01/2020
1	N(1)- pentadecanoyl- N(3'')- trifluoracetylkanamycin AIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 12/2019
1	abirateroneIBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Androgen Receptors (Androgen Receptor)IBA 01/2018
1	Phenobarbital (Luminal)FDA Link 02/2017
1	Insulin (Novolin)FDA Link 10/2016

Therapy/Procedure

11	Drug Therapy (Chemotherapy) 02/2024 - 01/2018
10	Therapeutics 04/2024 - 01/2018
10	Radiotherapy 03/2024 - 01/2019
5	Immunotherapy 03/2024 - 01/2014
5	Neoadjuvant Therapy 01/2024 - 01/2021
1	Drug Tapering 04/2024
1	Salvage Therapy 01/2023
1	Mastectomy (Mammectomy) 12/2022
1	Segmental Mastectomy (Lumpectomy) 12/2022
1	Radical Mastectomy 12/2022
1	Adjuvant Chemotherapy 06/2022
1	Combination Drug Therapy (Combination Chemotherapy) 01/2022
1	Aftercare (After-Treatment) 01/2021
1	Injections 01/2021